---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122779"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:36:49.146209+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amylyx reports Q3 net loss of $72.7M; cash $234.4M; pipeline updates on AMX0035, avexitide, AMX0114

## Summary
- Net loss of $72.7M ($1.07 loss per share) vs net income of $20.9M in Q3 2023; acquired IPR&D expense of $36.2M for avexitide.
- Cash, cash equivalents and marketable securities of $234.4M as of Sept. 30, 2024, down from $309.8M at June 30, 2024; runway into 2026.
- Positive Phase 2 HELIOS data for AMX0035 in Wolfram syndrome: met primary endpoint (C-peptide improvement), with stabilization across secondary measures.
- Avexitide Phase 3 program in post-bariatric hypoglycemia on track to initiate in Q1 2025; topline data expected in 2026.
- FDA placed clinical hold on AMX0114 ALS trial, requesting lower starting dose; Amylyx plans to start LUMINA trial in Canada by end of 2024/early 2025.

## SEC filing metadata
- accession: 0000950170-24-122779
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000095017024122779/0000950170-24-122779-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000095017024122779/amlx-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122779
- JSON: https://secwatch.observer/filing/0000950170-24-122779.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122779.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.